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ABSTRACT 
Objective: The purpose of this study is to see the correlation between iron overload with the hypogonadal state by analyzing the correlation 
between ferritin serum, transferrin saturation and pituitary MRI T2 relaxation time with FSH, LH and testosterone levels. 
Methods: This is a cross-sectional study of 32 male subjects with transfusion-dependent thalassemia. The subjects were collected with a 
consecutive sampling technique in the thalassemia outpatient clinic in National Hospital in Indonesia. Measurements of serum ferritin, transferrin 
saturation, FSH, LH and testosterone were taken using ELISA technique. Pituitary MRI T2 relaxation time was done using MRI Avanto 1.5 Tesla.  
Results: In this study, secondary sexual characteristics were not fully achieved in 62.5% of patients. Low testosterone levels were found in 25% of 
patients. There was a negative correlation between transferrin saturation and pituitary MRI T2 relaxation time in the normal testosterone level 
group.  
Conclusion: This study showed a high rate of patients who had not achieve puberty, but a low rate of patients with low testosterone, which means 
there is a weak negative correlation between transferrin saturation and pituitary MRI T2 relaxation times.  
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Hypogonadism, a disorder that leads to decreasing testosterone 
levels in men, may increase the risk of sexual dysfunction, mood 
disturbances and changes in bone mineral density and body 
composition [1]. Primary hypogonadism (hypogonadotropic 
hypogonadism) is indicated with low serum testosterone levels, but 
high levels of follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH); while secondary hypogonadism is characterized by 
low testosterone, FSH and LH levels [2, 3]. 
Hypogonadism is an endocrinal complication that occurs in 70–80% 
of major thalassemia patients. In these cases, hypogonadism is 
caused by iron build-ups in the pituitary gland, testes or both. This 
disorder is a hereditary condition caused by a defect in globin 
synthesis, which leads to impaired hemoglobin and requires patients 
to undergo blood transfusions. Beta-thalassemia is most common in 
the Mediterranean, Middle East, Asia, India, Southern China, 
Northern Africa and South America. The highest carrier frequency 
has been reported in Cyprus (14%), Sardinia (10.3%) and Southeast 
Asia [4-6]. 
Thalassemia major patients require regular red blood cell 
transfusions; this severe type of thalassemia is called transfusion-
dependent thalassemia (TDT). Transfusions results in excessive iron 
accumulation, which can lead to iron toxicity. The examination of 
blood iron levels is conducted by measuring the transferrin 
saturation (TSAT) and serum ferritin [4, 7–9]. 
A radiology technique, Magnetic Resonance Imaging (MRI), has been 
used and validated in various clinical trials as a useful modality for 
measuring iron deposits in an organ and has become a new standard 
for attaining these measurements. The assessment uses MRI T2* in 
the liver, heart and pancreas. However, due to the small size of the 
pituitary gland, spin-echo imaging (T2) is likely to perform better 
than T2* methods [8, 10-12]. 
Therefore, the aim of this study is to determine the correlation 
between serum ferritin, transferrin saturation, and excess iron levels 
in the pituitary gland (assessed by pituitary MRI T2). Along with, the 
correlation between excess iron levels in the pituitary gland and 
FSH, LH and testosterone levels in transfusion-dependent 
thalassemia in the Indonesian population. 
MATERIALS AND METHODS 
An analytic cross-sectional method was used in this study. The study 
was conducted in the adult thalassemia clinic and in the Department 
of Radiology of National Hospital in Indonesia, in the period of 
March–July 2019. The samples used were from male transfusion-
dependent thalassemia patients aged>18 y of age who were 
receiving transfusions in the thalassemia clinic during the period of 
the study. The exclusion criteria included the following:  
1. Subjects who experienced drug-induced hyperprolactinemia 
2. Subjects with a pituitary tumor 
3. Subjects with history of testicular trauma, irradiation or surgery 
4. Subjects with history of pituitary surgery 
Following approval from the Ethics Committee of the Faculty of 
Medicine in our university, informed consent was obtained from 
each subject. The convenient sampling technique was used. Based on 
the correlation test conducted, the minimum number of subjects 
needed were 32 patients. Data analysis was processed using the 
SPSS 21.0 program. Results were correlated and statistical analysis 
was conducted using Pearson’s correlation (r) for normally 
distributed data, and Spearman’s correlation (rho) test was used for 
data that was not normally distributed. 
Patients included in the study were recurring thalassemia patients 
who were receiving blood transfusions. The diagnosis of thalassemia 
was previously determined using high-performance liquid 
chromatography (HPLC) or a microcapillary examination. Plasma 
concentrations of serum ferritin and transferrin saturation were 
calculated using mean over a period of 12 mo. Serum ferritin 
measured using electrochemiluminescence immunoassay (ECLIA) 
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and transferrin saturation were obtained by dividing the serum iron 
total by the total iron-binding capacity. 
MRI examinations were performed using the Siemens MAGNETOM® 
Avanto 1.5T MRI to produce T2 SE sequences. The calculation of 
pituitary T2 relaxometry value was conducted using CMRtools™ 
software to determine iron deposits in various organs.  
The pituitary MRI T2* was assessed by multi-echo spin-echo (SE) 
sequence images (TR = 2000 ms; TE = 15, 30, 45, 60, 75, 90, 105 and 120 
ms; slice thickness = 3 mm; matrix size = 256 x 256; field of view [FOV] = 
20 cm) taken from the coronal view with a focus on the anterior pituitary 
gland. The scan duration was 8 min and 36 seconds. Calculations of the 
pituitary T2 SE relaxometry were done on the coronal plane. 
We determined the region of interest (ROI) on the T2 map of the 
pituitary gland without crossing organ boundaries and while 
avoiding bone structures. The segment option was then taken to 
provide the boundaries of the pituitary that were previously 
determined as the ROI. By selecting the analyze option, the T2 value 
for all images was automatically calculated, resulting in the average 
T2 value with a standard deviation in ms-units. The pituitary length 
measurement was done on the sagittal plane in mm-units.  
RESULTS 
Table 1 shows the subjects’ characteristics. Most of the patients 
were thalassemia ß-major (93.7%), while the rest were thalassemia 
ß-HbE (6.3%). A statistical test on age was conducted, and an 
abnormal distribution was obtained, with the median age of 22 y 
(minimum-maximum range is 18–39 y). 
Of the patients’ complaints relating to hypogonadism, erectile 
dysfunctions and decreased libido were reported in 9.4% and 21.8% 
of the cases, respectively. Not all patients have a family history 
related to delayed sexual growth. The body mass index (BMI) 
examination reported that 50% of the subjects were underweight, 
12% of the subjects were normal weight, 9.4% of the subjects were 
overweight and 3.1% of the subjects were obese. Of the 32 
transfusion-dependent thalassemia patients, 62% did not reach 
puberty according to their age (Tanner stage V), and 6 of them 
(18.75%) have hypogonadotropic hypogonadism. 
 
Table 1: Subjects’ characteristics 
Characteristics Total n = 32 
Age (years, median, minimum–maximum 22 (18–39) 
Thalassemia type, n (%) 
Thalasemia ß major 




Age, first received transfusion (months, median, minimum-maximum)  9 (3–72) 
Age, first received chelating agents (years), mean (SD) 6.28 (3.51) 
Chelating agents n (%) 
Deferiprone (Feriprox) 
Deferasirox (Exjade) 
Deferiprone and Deferasirox 







Table 1: Subjects’ characteristics (continued) 
Clinical, n (%)  















Physical examination, n (%)  





























Spleen size  
Not palpable 10 (31.3) 
S 1–4 15 (46.8) 
S 5–8 3 (9.4) 
Post-splenectomy 4 (12.5) 
Penile length (cm), median (minimum–maximum) 5.0 (2.0–7.0) 
Testicle size (ml), median (minimum-maximum) 20 (3–20) 
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Table 2 shows the patients’ sexual development clinical status. 
Sexual development is divided into clinical hypogonadism 
(Tanner stages I–IV) and fully developed of puberty (Tanner 
stage V). The clinical hypogonadism group showed higher serum 
ferritin and transferrin saturation than the normal testosterone 
group. Lower levels of FSH, LH and testosterone were observed, 
compared to the normal clinical group. Lower pituitary MRI T2 
relaxation times and shorter pituitary lengths were also 
observed in the clinical hypogonadism group when compared to 
the normal clinical group. 
 
Table 2: The study’s basic characteristics, based on clinical hypogonadism 
Characteristics Tanner stages I–IV Tanner stage V 
n=8 n=24 
Age (years), median (minimum–maximum) 22 (18–35) 21.5 (18–39) 






Transferrin saturation (%), mean (SD) 87.45 (10.14) 83.9 (11.5) 
FSH (mIU/ml), mean (SD) 5.98 (3.97) 7.2 (2.57) 
LH (mIU/ml), mean (SD) 6.09 (4.38) 8.4 (3.57) 
Testosterone (nmol/l), mean (SD) 17.13 (12.68) 33 (14.84) 
Pituitary MRI T2 time (ms), median (minimum–maximum) 69.44 (46.55–148.85) 74.21 (60.83–126.7) 
Pituitary length (mm), mean (SD) 5.7 (1.89) 6.06 (1.84) 
 
Descriptive data based on the patients’ testosterone levels can be 
seen in table 3. The low-testosterone group had higher serum 
ferritin and transferrin saturation, compared to the normal-
testosterone group. Lower pituitary length was also observed in the 
low-testosterone group, compared to the normal-testosterone 
group.
 
Table 3: The study’s basic characteristics, based on testosterone levels 
Characteristics Low testosterone Normal testosterone 
n=8 n=24 
Age (years), median (minimum–maximum) 23 (18–35) 21.5 (18–39) 
Serum ferritin (ng/ml), mean (SD) 9,870.05 (6,421.65) 6,846.90 (3,115.13) 
Transferrin saturation (%), mean (SD) 86.78 (8.95) 85.95 (11.30) 
Pituitary MRI T2 time (ms), median (minimum-maximum) 79.67 (46.55–96.55) 69.90 (47.71–148.85) 
Pituitary length (mm), mean (SD) 5.1 (1.7) 6.14 (1.84) 
There was no significant correlation found between serum ferritin and FSH levels, but there was a positive correlation between transferrin 
saturation and FSH level (table 4).  
 
Table 4: Correlation between FSH and serum ferritin levels and transferrin saturation 
Variables FSH 
r value p 
Serum ferritin 0.013 0.942 
Transferrin saturation 0.432 0.013 
There was no significant correlation found between serum ferritin and LH levels and transferrin saturation (table 5).  
 
Table 5: Correlation between LH level and serum ferritin levels and transferrin saturation 
Variables LH 
r value p 
Serum ferritin 0.029 0.875 
Transferrin saturation 0.157 0.390 
There was no significant correlation found between serum ferritin and testosterone levels and transferrin saturation; but there was a positive 
correlation between FSH and testosterone levels, and between LH and testosterone levels (table 6).  
 
Table 6: Correlation between testosterone and serum ferritin levels and transferrin saturation 
Variables Testosterone 
r value p 
Serum ferritin -0.021 0.911 
Transferrin saturation  0.087 0.635 
FSH 0.526 0.002 
LH 0.755 0.000 
There was no correlation found between pituitary MRI T2 relaxation time and serum ferritin, FSH, LH and testosterone levels and transferrin 
saturation (table 7). 
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Table 7: Correlation between pituitary MRI T2 relaxation time with the serum ferritin, FSH, LH and testosterone levels and transferrin 
saturation 
Variables Pituitary MRI T2 Relaxation Time 
r value p 
Serum ferritin - 0.178 0.329 
Transferrin saturation - 0.211 0.247 
FSH - 0.125 0.494 
LH 0.029 0.873 
Testosterone - 0.089 0.630 
This study found a negative correlation between serum ferritin levels and pituitary length. There was no correlation between pituitary length, 
pituitary MRI T2 relaxation time, transferrin saturation, and FSH and LH levels (table 8). 
 
Table 8: Correlation of pituitary length with pituitary MRI T2 relaxation time, serum ferritin, FSH and LH levels and transferrin saturation 
Variables Pituitary Length 
r value p 
Pituitary MRI T2 relaxation time -0.170 0.353 
Serum ferritin -0.442 0.011 
Transferrin saturation 0.067 0.715 
FSH 0.116 0.527 
LH 0.063 0.730 
 
In both the low-and normal-testosterone groups, there was a 
negative correlation between serum ferritin and pituitary MRI T2, 
even though this correlation was not statistically significant. In the 
normal-testosterone group, there was a positive correlation 
between pituitary length and pituitary MRI T2 relaxation time, and a 
negative correlation between transferrin saturation and pituitary 
MRI T2 relaxation time. There were significant correlations between 
FSH and LH levels in both groups (table 9). 
 
Table 9: Correlation between pituitary MRI T2 relaxation time with the serum ferritin, transferrin saturation, FSH and LH levels in low-
and normal-testosterone groups 
Variables Pituitary MRI T2 relaxation time 
Low testosterone Normal testosterone 
r value p r value p 
Pituitary length 0.251 0.548 0.463 0.023 
Serum ferritin -0.492 0.215 -0.053 0.807 
Transferrin saturation 0.592 0.122 -0.424 0.039 
FSH 0.558 0.151 -0.322 0.125 
LH 0.444 0.270 0.054 0.802 
 
DISCUSSION  
Correlation between serum ferritin and transferrin saturation 
and FSH, LH and testosterone levels 
In this study, excessive serum ferritin and transferrin saturation was 
found in 100% of the cases. However, serum ferritin levels did not 
correlate with FSH and LH levels. This is consistent with the study 
conducted by Abo-Elwafa et al., which stated that there was no 
correlation found between serum ferritin level and FSH, LH, 
oestradiol and testosterone levels after an analogue GnRH test was 
carried out [13]. Habeb et al. also found no significant association 
between serum ferritin levels and hypogonadism [14]. 
This current study also found a positive correlation between 
transferrin saturation and FSH level, but not between transferrin 
saturation and LH levels. FSH has a longer half-life than LH15. It was 
found that FSH has a complex secretion regulation due to various 
molecular factors that influence it, such as adiponectin, 
synaptotagmin 9 (syt-9) and ACTH [16]. We also found that both 
serum ferritin and transferrin saturation have negative correlations 
with testosterone levels, although this correlation was not 
statistically significant (r =-0.021, p = 0.991 and r =-0.016, and p = 
0.933, respectively).  
Several factors are thought to be related to hypogonadism and 
thalassemia patients. Chronic anemia can lead to hypoxic tissue, 
which impairs the function of endocrine organs. Belhoul et al. found 
that patients who experienced splenectomy are related to 
hypogonadism and not dependent on a patient’s ferritin levels, 
although the mechanism has not yet been explained. Liver damage, 
diabetes and hypothyroidism were reported to contribute to the 
prevalence of hypogonadism in the thalassemia population [17]. 
Correlation between pituitary MRI T2 time and serum ferritin, 
FSH, LH and testosterone levels and transferrin saturation 
In this study, there was no correlation found between MRI T2 values 
and blood-iron status (serum ferritin and transferrin saturation). 
Similarly, no significant correlation was found between pituitary 
MRI T2 values and FSH, LH and testosterone levels. This shows that 
iron build-ups in tissue causes an irreversible impact, even though 
blood iron levels decreased. In their study on this subject, Chatterjee 
et al. asserted that minimal organ damage was seen in patients with 
slightly increased iron levels and that this would lead to reversible 
hypogonadotropic hypogonadism. To the contrary, irreversible 
hypogonadism was seen in patients with excessive iron levels [18]. 
Correlation between pituitary length and MRI T2 relaxation 
time, serum ferritin, FSH and LH levels and transferrin 
saturation 
This study found a negative correlation between pituitary length and 
serum ferritin levels. The correlation between pituitary length and 
pituitary MRI T2 relaxation time was not found to be statistically 
significant. This is consistent with studies conducted by 
Cetincakmak et al. and Noetzli et al.; both studies reported that 
anterior pituitary height and pituitary volume did not correlate with 
T2* values. While iron build-ups in the pituitary gland can be 
reversible, the decrease in pituitary size is irreversible [12, 19]. 
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There was no correlation also found on pituitary length with FSH 
and LH level. To date, there have been no studies conducted on the 
relation of pituitary length to FSH and LH levels. 
Correlation between pituitary MRI T2 times and serum ferritin, 
FSH and LH levels and transferrin saturation in low-and 
normal-testosterone groups 
To improve the analysis, patients in this study were divided into 
subgroups based on their testosterone levels. The first group consisted 
of subjects whose testosterone level was<11.54 ng/ml (300 nmol/l), and 
the testosterone level of the subjects in the second group was>11.54 
ng/ml. There was a negative correlation between pituitary MRI T2 
relaxation time and transferrin saturation values (r =-0.424, p = 0.039) in 
the normal-testosterone group; no such correlation was found in the 
low-testosterone group. There was a positive correlation between 
pituitary length and pituitary MRI T2 relaxation time in the normal-
testosterone group; in the low-testosterone group, the correlation 
between these two factors was not significant, which is likely due to 
smaller pituitary size. The pituitary MRI T2 relaxation time examination 
is more challenging to conduct on patients with shorter pituitary length 
because it is more difficult to determine the ROI. 
CONCLUSION 
Based on the conducted study, high serum ferritin levels and 
transferrin saturation levels were found, but these levels did not 
correlate with FSH, LH and testosterone levels in male transfusion-
dependent thalassemia subjects. Moreover, there was no correlations 
found between serum ferritin levels and MRI T2 relaxation times; 
transferrin saturation levels and pituitary MRI T2 relaxation times; 
and pituitary MRI T2 relaxation times and FSH, LH and testosterone 
levels in male transfusion-dependent thalassemia subjects. 
We recommend that further research using a dynamic test (GnRH 
stimulation test) be conducted, followed with an evaluation of serial 
FSH and LH levels. In addition, a study with a control design should 
be conducted to observe changes in the pituitary structure and the 
impact of these changes on hormone levels and sexual development 
in transfusion-dependent thalassemia patients. Finally, further 
diagnostic-based research should be undertaken to determine the 
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